Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Reneo Pharmaceuticals Inc.
Headquarters: Irvine, CA, United States of America
Website: N/A
Year Founded: 2014
Status: Reverse-merged
BioCentury | Jan 18, 2025
Management Tracks
Moves at FDA, NIH
Plus: updates on AZ, Actimed, Kailera, Nasus and more
BioCentury | Sep 18, 2024
Management Tracks
New CEOs at Nura, IMU
Plus: Structure strengthens team and updates from RegenxBio, Mirador, Abata, Entact, Nautilus and more
BioCentury | May 17, 2024
Finance
Public Equity Report: Erasca reboots, Telix plans NASDAQ listing
Plus: OnKure goes public via reverse merger, Monte Rosa and Allogene each raise $100M+, and Incyte’s $2B buyback
BioCentury | May 14, 2024
Deals
Deals Report: Sanofi-Novavax to co-commercialize Nuvaxovid, develop combination vaccines
Plus: Maze finds Pompe disease program partner in Shionogi, and updates from Takeda-AC Immune, Sanofi-Fulcrum and more
BioCentury | Mar 9, 2022
Management Tracks
Oxford spinout MiroBio adds Keswani as CMO, promotes Murray to CSO
Plus updates from Centessa, Teon, AnchorDx, Pillar and more
BioCentury | Oct 12, 2021
Management Tracks
Novartis’ Baert joins Flagship
Plus: MacKenzie retiring from Pfizer, Ipsen, Ensoma, ChemoCentryx and more
BioCentury | Apr 13, 2021
Deals
April 12 Quick Takes: DiaSorin buying Luminex for $1.8B; plus Antios, Reneo, VectivBio, Pulmatrix, Taysha
DiaSorin S.p.A. (MTAA:DIA) is acquiring multiplexing technology company Luminex Corp. (NASDAQ:LMNX) for $1.8 billion in a deal that expands the Italian in vitro diagnostic company’s
BioCentury | Feb 3, 2021
Finance
Abingworth leans into company creation with largest-ever fund at $465M
Strong performance and continued broad interest in life sciences led to Abingworth raising its largest-ever fund, with the trans-Atlantic VC putting more energy into company creation and
BioCentury | Jan 21, 2021
Deals
Jan. 21 Quick Takes: Plexium extends series A, adds Grey as chair; plus Immunotech-T-Cure, Turnstone, reMYND, Gritstone-Genevant, Mitsubishi Tanabe-Aquestive, Mitsubishi Tanabe-Takeda
Preclinical protein degradation play Plexium Inc. raised $35 million in an extension of its series A round and appointed Mike Grey as chairman. The financing, led by Lux Capital and Pivotal
BioCentury | Dec 9, 2020
Product Development
Reneo to start pivotal trial in mitochondrial diseases, build orphan pipeline with Novo, Abingworth-led $95M series B
Company names Greg Flesher CEO
Items per page:
1 - 10 of 12